Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Medical Center, New York, New York.
Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, New York.
Ann Thorac Surg. 2018 Apr;105(4):1192-1198. doi: 10.1016/j.athoracsur.2017.10.043. Epub 2018 Feb 15.
Hospital readmissions have an adverse effect on the quality of life in patients with end-stage heart failure. We examined the temporal pattern, predictors, and outcomes of readmission in continuous flow left ventricular assist device-supported patients.
We retrospectively reviewed inpatient data of 350 consecutive patients who received a continuous-flow left ventricular assist device at our center between May 2004 and December 2014. A total time-restricted model was used to estimate hazard ratios for readmission, and the Nelson nonparametric method was used to estimate mean cumulative function for each cause of readmission.
The mean age was 57 ± 13 years, 82.6% received a HeartMate II (Abbott Laboratories, Chicago, IL), and 26.3% were destination therapy. The 30-day readmission rate was 21.7%, and 264 readmissions (41.1%) occurred within the first 6 months of support. The leading cause of readmission was bleeding (0.74 mean cumulative events per person), followed by infection (0.7), device failure (0.52), arrhythmia (0.3), and right heart failure (0.28) at 3 years. The number of readmissions did not have an adverse effect on survival (hazard ratio, 1.03; 95% confidence interval, 0.92 to 1.17; p = 0.58). Increase in each body mass index unit was associated with 1.029 times the rate of overall readmission (p = 0.041). Patients with a body mass index of 30 kg/m or higher had increased readmissions for device failure (p = 0.008) and right heart failure (p = 0.03).
Readmission burden is highest during the first few months of continuous-flow left ventricular assist device support, but survival is not affected. Patients with an elevated body mass index are at increased risk for readmissions for device failure and right heart failure.
心脏终末期心力衰竭患者的住院再入院对其生活质量有不良影响。我们研究了连续血流左心室辅助装置支持患者的再入院的时间模式、预测因素和结果。
我们回顾性分析了 2004 年 5 月至 2014 年 12 月期间在我院接受连续血流左心室辅助装置治疗的 350 例连续患者的住院数据。采用全时限制模型估计再入院的风险比,采用纳尔逊非参数法估计每种再入院原因的平均累积函数。
平均年龄为 57±13 岁,82.6%的患者接受了 HeartMate II(雅培公司,芝加哥,IL)治疗,26.3%的患者为终末期心力衰竭治疗。30 天再入院率为 21.7%,264 例(41.1%)再入院发生在支持治疗的前 6 个月内。再入院的主要原因是出血(0.74 人平均累积事件),其次是感染(0.7)、装置故障(0.52)、心律失常(0.3)和右心衰竭(0.28)。再入院次数对生存率没有不良影响(风险比,1.03;95%置信区间,0.92 至 1.17;p=0.58)。每增加 1 个体重指数单位与整体再入院率增加 1.029 倍相关(p=0.041)。体重指数为 30kg/m 或更高的患者因装置故障(p=0.008)和右心衰竭(p=0.03)而增加了再入院。
在连续血流左心室辅助装置支持的最初几个月内,再入院负担最高,但生存不受影响。体重指数升高的患者因装置故障和右心衰竭而再入院的风险增加。